SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt
MWN-AI** Summary
A recent securities class action lawsuit has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) amid allegations that the company conducted sham clinical trials for its sole commercial product, DCCR, marketed as VYKAT XR, intended to treat hyperphagia in patients with Prader-Willi syndrome. The lawsuit claims that investors who purchased Soleno securities between March 26 and November 4, 2025, may have suffered significant losses due to misrepresentations regarding the integrity of clinical trial data and drug safety.
Central to the lawsuit is the accusation that Soleno's pivotal Phase 3 clinical trial program was compromised and unreliable. The FDA approval of DCCR hinged entirely on data from a 16-week randomized withdrawal study, which involved a notably small participant pool of just 77 individuals, raising concerns about the representativeness of the results. Critics allege that the original Phase 3 trial failed to meet its primary endpoint, and that there were issues related to unblinding which could have introduced placebo bias.
The complaint highlights additional safety concerns, noting that fluid retention—a known risk related to the drug's mechanism—was downplayed despite reports of severe complications, including pulmonary edema and heart failure in patients. The lawsuit asserts that Soleno's management misled investors by asserting a "well-established safety profile" for DCCR, despite evidence suggesting otherwise.
Investors have until May 5, 2026, to seek lead plaintiff status in this class action. The allegations paint a troubling picture regarding the clinical trial integrity that underpins not only DCCR's approval but also Soleno's financial viability, heightening scrutiny on the company amidst increasing investor skepticism.
MWN-AI** Analysis
The recent lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) highlights pressing concerns about the integrity of its clinical trials and poses significant risks for investors. The allegations center on purported misrepresentations regarding the safety and efficacy of DCCR (VYKAT XR), the company’s only commercial product aimed at treating hyperphagia in patients with Prader-Willi syndrome. With claims focusing on serious deficiencies in the Phase 3 clinical trial, the market's confidence in Soleno's future appears to be waning.
Investors should closely monitor the developments of this lawsuit, especially given the pivotal role of Soleno's clinical data in securing FDA approval. The critical randomized withdrawal study involved only 77 participants—a small cohort that raises concerns about the robustness of the data. Moreover, reported issues such as placebo bias, insufficient sample diversity, and negative feedback from key medical professionals add layers of uncertainty. The lawsuit claims that management downplayed adverse events associated with DCCR, including increased risk factors for prediabetes and fluid retention complications.
In light of these allegations, potential investors may want to adopt a cautious approach. With the deadline for interested parties to seek lead plaintiff status looming on May 5, 2026, the outcome of this litigation could significantly influence SLNO’s stock price and investor sentiment.
Those considering investing in Soleno should conduct thorough due diligence, reassess risk tolerance, and weigh the implications of the lawsuit’s findings on the company’s reputation, market position, and revenue potential. A prudent course of action may be to hold off on new investments until the legal challenges are resolved and a clearer picture of Soleno’s operational stability emerges.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Alert: Claims Focus on Alleged Misrepresentations About Clinical Trial Integrity and Drug Safety
NEW YORK, March 12, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Soleno Therapeutics, Inc. (NASDAQ: SLNO) securities of a pending securities class action.
THE CASE: A class action seeks to recover damages for investors who purchased Soleno securities between March 26, 2025 and November 4, 2025.
YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Soleno's sole commercial product, DCCR (marketed as VYKAT XR), is a diazoxide choline extended-release tablet for treating hyperphagia in patients with Prader-Willi syndrome. The drug's FDA approval rested entirely on Soleno's Phase 3 clinical trial program, including a pivotal 16-week randomized withdrawal study. Investors have until May 5, 2026 to seek lead plaintiff status.
How DCCR Reaches Patients and Why Trial Integrity Allegedly Matters
A pharmaceutical company cannot sell a drug without FDA approval. That approval depends on demonstrating safety and efficacy through well-controlled clinical trials. For Soleno, the entire commercial opportunity for DCCR hinged on one pivotal study: the randomized withdrawal period of Study C602. If that study's data was unreliable, the foundation for the drug's approval, its commercial launch, and Soleno's revenue was fundamentally compromised.
The lawsuit contends that Soleno's Phase 3 program suffered from systematic problems that defendants knew about or recklessly disregarded.
Alleged Clinical Trial Deficiencies by the Numbers
- The pivotal randomized withdrawal study enrolled only 77 participants, an unusually small sample, with enrollment allegedly skewed heavily toward a single clinical site
- The original 13-week Phase 3 trial (DESTINY PWS, n=127) failed to meet its primary endpoint for hyperphagia improvement, as the filing states
- Investigators reportedly identified placebo bias from unblinding caused by visible side effects such as hypertrichosis (excessive hair growth) and edema, as well as differing smell between drug and placebo
- Many investigators interviewed by an independent research firm allegedly expressed sharp criticism of trial conduct and indicated no plans to prescribe the drug
- A number of endocrinologists across major academic centers and PWS clinics reportedly expressed similar skepticism about the drug's safety profile
- The action claims defendants obscured a linear increase in prediabetes and diabetes markers over three years of treatment with no plateau
Fluid Retention and the Alleged Safety Concealment
The complaint recounts that fluid retention is inherent to diazoxide's mechanism of action. As detailed in the action, two patients in the 13-week Phase 3 trial may have been admitted for symptoms consistent with pulmonary edema and potential heart failure, but these events were allegedly downplayed. The lawsuit chronicles how the prevalence of edema appeared to increase the longer patients used the drug, with no apparent plateau, suggesting a tipping point between discontinuation or a serious safety event.
Despite these concerns, management repeatedly told investors the drug had a "well-established safety profile" and that "no new safety signals" had emerged in the postmarketing setting.
Calculate your potential recovery or call (212) 363-7500.
"The complaint raises serious questions about whether investors received accurate information regarding the integrity of the clinical data underpinning DCCR's approval and commercial launch." -- Joseph E. Levi, Esq.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
SOURCE SueWallSt.com
FAQ**
How might the allegations against Soleno Therapeutics Inc. SLNO regarding clinical trial integrity impact investor sentiment and confidence in the company moving forward?
What specific measures can Soleno Therapeutics Inc. SLNO take to address the concerns raised in the lawsuit and reassure stakeholders about the safety and efficacy of DCCR?
In what ways could the outcome of the securities class action against Soleno Therapeutics Inc. SLNO influence future FDA approvals and the company's ability to fund further research and development?
How have the alleged shortcomings in the clinical trials for DCCR affected Soleno Therapeutics Inc. SLNO's market performance since the lawsuit was announced?
**MWN-AI FAQ is based on asking OpenAI questions about Soleno Therapeutics Inc. (NASDAQ: SLNO).
NASDAQ: SLNO
SLNO Trading
-8.84% G/L:
$33.52 Last:
2,079,152 Volume:
$36.44 Open:
